Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines
- PMID: 22206075
Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines
Abstract
Background: Injections of botulinum toxin type A are commonly used to treat facial wrinkles; however, undesirable effects are associated with injections (e.g., pain, bruising, ptosis, immunogenicity, and needle aversion). To address these issues, RT001 Botulinum Toxin Type A Topical Gel is being developed for the treatment of lateral canthal lines.
Objectives: To assess the safety and efficacy of RT001 for the treatment of lateral canthal lines in a randomized, double-blind, placebo-controlled study.
Materials & methods: Adult subjects were enrolled to receive a single treatment of RT001 (n=45) or placebo (n=45) applied topically in the lateral canthal area. The primary endpoint was the composite of the Investigator Global Assessment of Lateral Canthal Line Severity (IGA-LCL) and the Patient Severity Assessment of lateral canthal line severity (PSA) defined as a 2-point or greater improvement on both scales.
Results: At four weeks, 44.4 percent of subjects treated with RT001 achieved a 2-point or greater improvement on a rigorous composite of both the IGA-LCL and PSA scales compared to 0.0% for the placebo subjects (P<0.0001). At four weeks, 88.9 percent of subjects achieved clinically relevant improvement by investigator assessment. Adverse events were mild in severity and unrelated to study treatment.
Conclusions: RT001 appears to be a safe and well-tolerated treatment for improvement of lateral canthal lines.
Similar articles
-
Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines.Dermatol Surg. 2010 Dec;36 Suppl 4:2111-8. doi: 10.1111/j.1524-4725.2010.01711.x. Dermatol Surg. 2010. PMID: 21134043 Clinical Trial.
-
Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines.Dermatol Surg. 2011 Jul;37(7):1060. doi: 10.1111/j.1524-4725.2011.02067.x. Dermatol Surg. 2011. PMID: 21711409 No abstract available.
-
Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.Dermatol Surg. 2009 Oct;35(10):1478-86. doi: 10.1111/j.1524-4725.2009.01261.x. Epub 2009 Jul 20. Dermatol Surg. 2009. PMID: 19686365 Clinical Trial.
-
Cosmetic oculofacial applications of botulinum toxin: a report by the American Academy of Ophthalmology.Ophthalmology. 2005 Jun;112(6):1159-67. doi: 10.1016/j.ophtha.2005.03.021. Ophthalmology. 2005. PMID: 15936443 Review.
-
Cosmetic applications of botulinum toxin in oculofacial region.Acta Clin Croat. 2010 Dec;49(4):525-8. Acta Clin Croat. 2010. PMID: 21830467 Review.
Cited by
-
Two-pore channels regulate Tat endolysosome escape and Tat-mediated HIV-1 LTR transactivation.FASEB J. 2020 Mar;34(3):4147-4162. doi: 10.1096/fj.201902534R. Epub 2020 Jan 16. FASEB J. 2020. PMID: 31950548 Free PMC article.
-
Novel cell-penetrating peptide-adaptors effect intracellular delivery and endosomal escape of protein cargos.J Cell Sci. 2016 Mar 1;129(5):893-7. doi: 10.1242/jcs.182113. Epub 2016 Jan 22. J Cell Sci. 2016. PMID: 26801086 Free PMC article.
-
Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress.Biomedicines. 2023 Jul 12;11(7):1971. doi: 10.3390/biomedicines11071971. Biomedicines. 2023. PMID: 37509610 Free PMC article. Review.
-
Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder.J Urol. 2017 Apr;197(4):982-990. doi: 10.1016/j.juro.2016.11.092. Epub 2016 Nov 18. J Urol. 2017. PMID: 27871929 Free PMC article.
-
Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment.Clin Pharmacol. 2021 Nov 25;13:209-223. doi: 10.2147/CPAA.S289323. eCollection 2021. Clin Pharmacol. 2021. PMID: 34858068 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous